SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001328143-21-000075
Filing Date
2021-11-10
Accepted
2021-11-10 16:02:00
Documents
68
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q adms-20210930.htm   iXBRL 10-Q 1527611
2 EX-31.1 adms10qq32021ex311.htm EX-31.1 11552
3 EX-31.2 adms10qq32021ex312.htm EX-31.2 11919
4 EX-32.1 adms10qq32021ex321.htm EX-32.1 8726
  Complete submission text file 0001328143-21-000075.txt   6152833

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210930.xsd EX-101.SCH 37438
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20210930_cal.xml EX-101.CAL 64791
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20210930_def.xml EX-101.DEF 199613
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210930_lab.xml EX-101.LAB 514878
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210930_pre.xml EX-101.PRE 329422
10 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210930_htm.xml XML 918154
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 211396432
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences